Dr. Robert Kaufman and the new ValidCare Safety Study on CBD
Jonathan Miller interviews Dr. Robert Kaufman, the Director of research for ValidCare, a leading national independent research firm that recently completed a safety study on orally-ingested CBD. The study provides data that addresses FDA’s specific safety concerns regarding CBD, and has led to renewed industry calls urging FDA to regulate CBD now. If you have questions about the episode or ideas for hemp related topics, email us at hemplegallyspeaking@fbtlaw.com.
Hemp Industry Episode Resources:
Host: Jonathan Miller
Guest: Dr. Robert Kaufman
Blog: Hemp Legally Speaking
Hemp Industry questions covered in the episode:
Host: Jonathan Miller
Guest: Dr. Robert Kaufman
Blog: Hemp Legally Speaking
Hemp Industry questions covered in the episode:
- What does the ValidCare study demonstrate about the safety of ingestible CBD?
- What did the study conclude about CBD’s liver toxicity and how does this contrast with studies done on Epidiolex, the CBD drug used by children with rare forms of epilepsy?
- How does the study address concerns about drowsiness and low testosterone?
- Statistically speaking, how strong are the study’s conclusions
- What’s the message that Dr. Kaufman will be sharing with FDA in its upcoming meeting?